Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Receivables (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Receivables for 15 consecutive years, with $12.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables fell 0.53% year-over-year to $12.1 million, compared with a TTM value of $12.1 million through Sep 2025, down 0.53%, and an annual FY2024 reading of $1.1 million, down 86.6% over the prior year.
  • Receivables was $12.1 million for Q3 2025 at Sanara MedTech, up from $9081.0 in the prior quarter.
  • Across five years, Receivables topped out at $12.2 million in Q3 2024 and bottomed at $9081.0 in Q2 2025.
  • Average Receivables over 5 years is $4.6 million, with a median of $2.9 million recorded in 2021.
  • The sharpest move saw Receivables plummeted 98.45% in 2024, then surged 51467.26% in 2025.
  • Year by year, Receivables stood at $2.9 million in 2021, then soared by 137.27% to $6.9 million in 2022, then increased by 23.44% to $8.5 million in 2023, then tumbled by 86.6% to $1.1 million in 2024, then skyrocketed by 958.26% to $12.1 million in 2025.
  • Business Quant data shows Receivables for SMTI at $12.1 million in Q3 2025, $9081.0 in Q2 2025, and $11.9 million in Q1 2025.